{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:23:36Z","timestamp":1787181816739,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.breast.2022.09.005","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T08:50:56Z","timestamp":1664009456000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer"],"prefix":"10.1016","volume":"66","author":[{"given":"Amit","family":"Bahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-888X","authenticated-orcid":false,"given":"Jessica","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2244-7503","authenticated-orcid":false,"given":"Emily","family":"Renninson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Foulstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiqa","family":"Spensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pippa","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Bezecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Madhusudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Verrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1943-7360","authenticated-orcid":false,"given":"Jeremy","family":"Braybrooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Comins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6833-4611","authenticated-orcid":false,"given":"Alison","family":"Markham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Callaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Hackshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Churn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2022.09.005_bib1","author":"World Health Organization"},{"key":"10.1016\/j.breast.2022.09.005_bib2","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)dagger","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.breast.2022.09.005_bib3","series-title":"Managing advanced breast cancer\u201d","year":"2020"},{"issue":"5","key":"10.1016\/j.breast.2022.09.005_bib4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/annonc\/mdm008","article-title":"Inclusion of taxanes, particularly weekly Paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers","volume":"18","author":"Mazouni","year":"2007","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.breast.2022.09.005_bib5","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Siedman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.breast.2022.09.005_bib6","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","article-title":"Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks","volume":"23","author":"Green","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2022.09.005_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/annonc\/mdi056","article-title":"Weekly Paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)","volume":"16","author":"Del Mastro","year":"2005","journal-title":"Ann Oncol"},{"issue":"2\u20133","key":"10.1016\/j.breast.2022.09.005_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000085620","article-title":"Weekly Paclitaxel in the treatment of advanced or metastatic breast cancer previously treated or not treated with docetaxel: a phase II study","volume":"51","author":"Nishimura","year":"2005","journal-title":"Chemotherapy"},{"issue":"10","key":"10.1016\/j.breast.2022.09.005_bib9","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.1998.16.10.3353","article-title":"Dose-dense therapy with weekly 1-hour Paclitaxel infusions in the treatment of metastatic breast cancer","volume":"16","author":"Seidman","year":"1998","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.breast.2022.09.005_bib10","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1200\/JCO.2001.19.22.4216","article-title":"Multicenter phase II trial of weekly Paclitaxel in women with metastatic breast cancer","volume":"19","author":"Perez","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2022.09.005_bib11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/030089160208800607","article-title":"Weekly Paclitaxel in metastatic breast cancer patients: a phase II study","volume":"88","author":"Gori","year":"2002","journal-title":"Tumori Journal"},{"issue":"8","key":"10.1016\/j.breast.2022.09.005_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jjco\/hyg075","article-title":"Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the saitama breast cancer clinical study group (SBCCSG-01)","volume":"33","author":"Sato","year":"2003","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2022.09.005_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/030089160409000304","article-title":"Long-term, weekly one-hour infusion of Paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study","volume":"90","author":"Lombardi","year":"2004","journal-title":"Tumori Journal"},{"issue":"3","key":"10.1016\/j.breast.2022.09.005_bib14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejca.2003.08.013","article-title":"Weekly Paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial","volume":"40","author":"ten Tije","year":"2004","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2022.09.005_bib15","first-page":"1076","article-title":"Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes","volume":"21","author":"Kucukozstas","year":"2016","journal-title":"JBUON"},{"key":"10.1016\/j.breast.2022.09.005_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in Paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2022.09.005_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1470-2045(07)70041-4","article-title":"Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial","volume":"8","author":"Martin","year":"2007","journal-title":"Lancet Oncol"},{"issue":"9769","key":"10.1016\/j.breast.2022.09.005_bib18","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2022.09.005_bib19","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/DDDT.S64940","article-title":"Preclinical profile of cabazitaxel","volume":"8","author":"Vrignaud","year":"2014","journal-title":"Drug Des Dev Ther"},{"issue":"9747","key":"10.1016\/j.breast.2022.09.005_bib20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus Cabazitaxel or mitoxantrone for metastatic castration-resisant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2022.09.005_bib21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdn171","article-title":"A multicentre phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients","volume":"19","author":"Pivot","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2022.09.005_bib22","first-page":"1","article-title":"Phase 2 study of Cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes\u2014a Hellenic Cooperative Oncology Group (HeCOG) Trial","author":"Koutras","year":"2020","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.breast.2022.09.005_bib23","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ejca.2011.01.001","article-title":"A multicentre dose-escalating study of Cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I\/II study","volume":"47","author":"Villanueva","year":"2011","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2022.09.005_bib24","doi-asserted-by":"crossref","first-page":"e781","DOI":"10.1016\/j.clbc.2018.03.004","article-title":"Cabazitaxel plus lapatinib as therapy for HER2+ metastatic breast cancer with intracranial metastases: results of a dose-finding study","volume":"18","author":"Yardley","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2022.09.005_bib25","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.breast.2022.09.005_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/cer.14.76","article-title":"EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review","volume":"4","author":"Nguyen","year":"2015","journal-title":"Journal of comparative effectiveness research"},{"issue":"1","key":"10.1016\/j.breast.2022.09.005_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11764-014-0379-x","article-title":"Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer","volume":"9","author":"Jones","year":"2015","journal-title":"Journal of Cancer Survivorship"},{"issue":"4","key":"10.1016\/j.breast.2022.09.005_bib29","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jval.2016.11.015","article-title":"Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores","volume":"20","author":"McClure","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.breast.2022.09.005_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcome"},{"issue":"9","key":"10.1016\/j.breast.2022.09.005_bib31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","article-title":"A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale","volume":"57","author":"Eton","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.breast.2022.09.005_bib32","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2022.09.005_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.06.037","article-title":"Randomised, open-label, phase II study comparing the efficacy and the safety of Cabazitaxel versus weekly Paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B\/HER2-negative breast cancer (GENEVIEVE)","volume":"84","author":"K\u00fcmmel","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762200159X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762200159X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:45:28Z","timestamp":1760777128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762200159X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":32,"alternative-id":["S096097762200159X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2022.09.005","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2022.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}